Study of CTS-1027 in Hepatitis C Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Clinical Trial Description

Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00570336
Study type	Interventional
Source	Conatus Pharmaceuticals Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	December 2007
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01708889` - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction	Phase 1
Active, not recruiting	`NCT00563173` - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients	Phase 1/Phase 2
Withdrawn	`NCT01813266` - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed	`NCT01121731` - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C	Phase 1/Phase 2
Completed	`NCT00851890` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection	Phase 2
Completed	`NCT04391985` - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients	Phase 1/Phase 2
Completed	`NCT04387539` - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants	Phase 1/Phase 2
Completed	`NCT00770198` - sgp130 in Chronic Human Liver Disease	N/A
Completed	`NCT04382937` - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection	Phase 3
Completed	`NCT00606528` - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy	N/A
Recruiting	`NCT00294489` - Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT	Phase 3
Withdrawn	`NCT00255359` - Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers	Phase 1
Completed	`NCT02292719` - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection	Phase 2
Terminated	`NCT01080222` - A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection	Phase 2
Completed	`NCT04385407` - Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients	Phase 2
Completed	`NCT04387526` - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4	Phase 2/Phase 3
Completed	`NCT00215865` - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy	Phase 3